GSK's new R&D head bets on genetics with $300 million 23andMe deal

GlaxoSmithKline's new research boss aims to turbo-charge the British group's drug discovery engine with a $300 million bet on genetics by buying a stake in the Silicon Valley gene testing company 23andMe.